Simultaneous pharmacokinetic assessment of cefadroxil and clavulanic acid in human plasma by LC–MS and its application to bioequivalence studies  by Nagarajan, Janaki Sankarachari Krishnan et al.
Contents lists available at ScienceDirect
www.elsevier.com/locate/jpa
Journal of Pharmaceutical Analysis
Journal of Pharmaceutical Analysis 2013;3(4):285–2912095-1779 & 2013 Xi
http://dx.doi.org/10.1
nCorresponding au
E-mail address: a
Peer review underwww.sciencedirect.comORIGINAL ARTICLE
Simultaneous pharmacokinetic assessment of cefadroxil and
clavulanic acid in human plasma by LC–MS and its
application to bioequivalence studiesJanaki Sankarachari Krishnan Nagarajan, Chandran Sathish Vimal,
Renjith George, Anil DubalanDepartment of Pharmaceutical Analysis, J.S.S. College of Pharmacy, Udhagamandalam, Tamilnadu, India
Received 4 August 2012; accepted 4 February 2013
Available online 26 February 2013KEYWORDS
Cefadroxil;
Clavulanic acid;
LC–MS;
APCI;
Pharmacokinetics;
Bioequivalence’an Jiaotong Univ
016/j.jpha.2013.02
thor. Tel.: þ91 967
nildubala@gmail.c
responsibility of XAbstract A simple, rapid and selective liquid chromatography–atmospheric pressure chemical
ionization–mass spectrometry (LC–APCI–MS) assay method has been developed and fully
validated for the simultaneous quantiﬁcation of cefadroxil (CF) and clavulanic acid (CA) in
human plasma. Analytes and internal standard (IS) were extracted from human plasma by solid-
phase extraction (SPE) technique using Sam prep (3 mL, 100 mg) extraction cartridge. The
extracted samples were chromatographed on a reverse phase C18 column using a mixture of
methanol: acetonitrile: 2 mM ammonium acetate (pH 3.5) (25:25:50, v/v/v) as the mobile phase at a
ﬂow rate of 0.8 mL/min. Quantiﬁcation of the analytes and IS were carried out using single
quadrupole LC–APCI–MS through selected-ion monitoring (SIM) at m/z 362 and m/z 198, for CF
and CA, respectively. Method validation was performed as per the FDA guidelines and the results
met the acceptance criteria. Plasma concentration of CF and CA followed by the oral
administration of CF/CA (500/125 mg) pill to healthy male volunteers (n¼12) was measured.
Area under plasma concentration–time curve from 0 to 12 h (AUC0–12 h) and 0 h extrapolated to
inﬁnity (AUC0N) were calculated. The ratio of AUC0–12 h/AUC0N was found to be 485% for
all the subjects, as recommended by the FDA guidelines.
& 2013 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.ersity. Production and hosting by E
.003
7448929.
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i’an Jiaotong University.1. Introduction
Cefadroxil (CF) (8-[2-amino-2-(4-hydroxyphenyl)-acetyl]amino-
4-methyl-7-oxo-2thia-6-azabicyclo-[4.2.0]oct-4-ene-5-carboxylic
acid, C16H17N3O5S, MW 363.3), is a broad-spectrum ﬁrst
generation cephalosporin, used in the treatment of urinary
tract infections. It has signiﬁcant activity against bothlsevier B.V. All rights reserved.
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(CA) ((Z)-(2R, 5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-
azabicyclo[3.2.0]-heptane-2-carboxylate, C8H9NO5, MW 199.2),
is a beta-lactamase inhibitor. Plasmid mediated beta-lactamases
are responsible for transferred drug resistance to beta-lactam
antibiotics, such as penicillin and cephalosporin’s. CA covalently
binds to a serine residue in the active site of the beta-lactamase,
and inhibits them. This inhibition restores the antimicrobial
activity of beta-lactam antibiotics against lactamase-secreting
resistant bacteria.
A number of analytical methods have been reported for
quantiﬁcation of CF [1–17] and CA [18–22] individually or
with other drugs in biological samples. To the best of our
information, only one method has been reported for the
simultaneous determination of CF and CA [23]. To date, no
liquid chromatography mass spectrometry (LC–MS) method
has been reported for the simultaneous determination of CF
and CA in human plasma. The present work describes a
simple, selective and sensitive method, which employs a simple
solid-phase extraction (SPE) technique for sample preparation
and LC–MS for the simultaneous quantitation of CF and CA
in human plasma. The application of this assay method to a
clinical pharmacokinetic study in healthy male volunteers
following oral single pill administration of CF and CA is
described.2. Experimental
2.1. Chemicals and reagents
Working standards of CF (99.9% pure), potassium clavula-
nate (99.9% pure), chloramphenicol (99.9% pure) (Internal
standard, IS) and CF/CA (500/125 mg) pills were obtained
from Macleods Pharmaceuticals Pvt. Ltd. (Mumbai, India).
Water used for the LC–MS analysis was prepared from Milli
Q water puriﬁcation system procured from Millipore (Banga-
lore, India). HPLC grade methanol and acetonitrile were
procured from Merck (Mumbai, India). All other chemicals
and solvents of analytical grade were purchased from Merck
(Mumbai, India). Sam prep (3 mL, 100 mg) extraction car-
tridge was purchased from Ranbaxy ﬁne chemicals Ltd.
(New Delhi, India). Pooled plasma was collected from healthy,
drug-free volunteers and stored at 2072 1C until analysis.
2.2. Preparation of calibration standards and quality
control samples
Calibration samples were prepared by spiking 950 mL of
control human plasma with the appropriate working standard
solution of the each analyte (25 mL dilution of CF and 25 mL
of CA). Calibration curve standards consisting of a set of eight
non-zero concentrations ranging from 5.0 to 30000.0 ng/mL
for CF and 2.0 to 12000.0 ng/mL for CA were prepared.
Quality control samples (QCs) at a minimum of three
concentrations (lower quality control (LQC), middle quality
control (MQC), and high quality control (HQC)) were prepared
by spiking the working standard solution into a pool of drug
free human plasma. The QCs prepared for each analyte are 15.0
(LQC), 15000.0 (MQC) and 25000.0 ng/mL (HQC) for CF and
10.0 (LQC), 5000.0 (MQC) and 9000.0 ng/mL (HQC) for CA.
All the samples were stored at 2072 1C for subsequent use.2.3. Sample processing
A 500 mL aliquot of human plasma sample was mixed with
500 mL of the IS working solution (100 mg/mL) and vortexed
for 10 s. The sample mixture was loaded onto a Sam prep
(3 mL, 100 mg) extraction cartridge that was pre-conditioned
with 1.0 mL of methanol followed by 1.0 mL water. The
extraction cartridge was washed with 2.0 mL of water. CF,
CA and IS were eluted with 0.5 mL of mobile phase. Aliquot
of 20 mL of the extract was injected into the LC–MS.
2.4. LC–MS analysis
Shimadzu LCMS-2010A (Shimadzu Corporation, Kyoto, Japan)
consisting of Phenomenex C18 column (150 mm 4 mm i.d.,
5 mm), LC-10 AD-Vp solvent delivery system (pump), SIL 10
AD-Vp auto injector, CTO 10 Vp column oven, DGU 14AM de
gasser was used for the study. Aliquots of the processed samples
(20 mL) were injected into the column, which was kept at 20 1C.
The isocratic mobile phase, a mixture of methanol: acetonitrile:
2 mM ammonium acetate (pH 3.5) (25:25:50, v/v/v) was deliv-
ered at 0.8 mL/min into the atmospheric pressure chemical-
ionization (APCI) chamber of the mass spectrometer. Quantita-
tion of CF, CA and IS was performed on the single quadrupole
mass spectrometer in the negative ion mode. The ion source
temperature, desolvation temperature, and the capillary voltage
were set at 400 1C, 250 1C, and 1.3 kV, respectively. Detection of
the ions was carried out in the selected-ion monitoring (SIM)
mode, at m/z 362 for CF, m/z 198 for CA, and m/z 322 for the
IS. The analysis data obtained were processed by LC–MS
solutions data station.
2.5. Method validation
Method validation of CF and CA in human plasma was
performed as per the US FDA guidelines [26]. The assay was
validated for speciﬁcity, linearity, sensitivity, accuracy, preci-
sion, extraction recovery, matrix effect and stability.
Speciﬁcity of the method was determined by analyzing six
different lots of human plasma samples. The responses of the
interfering substances or background noises at the retention
time of CF and CA are acceptable if they are less than 20% of
the response of the lowest standard curve point or lower limit
of quantiﬁcation (LLOQ).
Linearity was tested for CF and CA in the concentration
range of 5.0–30000.0 and 2.0–12000.0 ng/mL, respectively. For
the determination of linearity, standard calibration curves
containing eight points (non-zero standards) were plotted and
checked. The acceptance limit of accuracy for each of the
back-calculated concentrations is715% except LLOQ, where
it is 720%. For a calibration run to be accepted at least 67%
of the standards, the LLOQ and upper limit of quantiﬁcation
(ULOQ) are required to meet the acceptance criterion, other-
wise the calibration curve was rejected. Six replicate analyses
were performed on each calibration standard. Sensitivity was
established from the background noise or response from six
spiked LLOQ samples. The six replicates should have a
precision of 720% and an accuracy of 720%.
Intra-, inter-day assay precision and accuracy were deter-
mined by analyzing six replicates at three different QCs levels
on three independent days. The acceptance criteria included
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precision of 715% coefﬁcient of variation (CV).
Recoveries of CF, CA and IS were determined by compar-
ing the peak area of extracted analyte standard (A) with the
peak area of non-extracted standard (B) at the same nominal
concentrations. The ratio (A/B 100)% was deﬁned as the
extraction efﬁciency. The extraction recovery of CF and CA
were determined at concentrations of 15.0 and 5.0 (LQC),
15000.0 and 5000.0 (MQC), and 25000.0 and 9000.0 ng/mL
(HQC), respectively, where as for IS was determined at a
concentration of 100.0 mg/mL.
Matrix effects were evaluated by comparing peak areas of
post-extraction blank plasma spiked with QC solutions with
peak areas of post-extraction aqueous blank samples spiked
with QC solutions. The acceptance criteria included matrix
effect should be within 715% from the nominal values.
Stability of CF and CA in biological matrix was determined
by the analysis of six replicates of QCs (n¼3) exposed to
various storage conditions. For freeze–thaw stability studies,
QCs were subjected to freeze-thaw (3 cycles). Each sample was
stored at 20 1C for 24 h and thawed at room temperature,
after which the samples were refrozen for 12–24 h under the
same conditions. At the end of each cycle, the samples were
processed, analyzed and compared with the freshly prepared
QCs. For the short-term and stock solution stability study,
QCs were kept at 25 1C for 6 h and samples were processed at
different time points and were analyzed and compared with
the freshly prepared QCs. To assess the long-term stability,
QCs were stored at 20 1C for 3 months, which exceeds the
time between sample collection and sample analysis.
2.6. Application
Validated method was applied to measure the plasma con-
centration of CF and CA in human plasma after oral
administration of CF/CA (500/125 mg) pill to healthy male
volunteers (n¼12).
2.7. Clinical design
A clinical study was performed in healthy male subjects
(n¼12). The institutional review board of JSS College of
Pharmacy, Udhagamandalam, India, approved the protocolFig. 1 Chemical structure and massand the volunteers provided with informed written consent.
The study was conducted in compliance with the ethical
guidelines for biomedical research on human participants
(2006) published by Indian council of medical research
(ICMR), New Delhi. Twelve healthy male subjects were
randomized into two groups, consisted of six in each group.
A randomized open label crossover study was conducted with
two treatment phases, separated by a two-week washout
period. Blood samples (5 mL) were collected following oral
administration of 500/125 mg ﬁxed dose combination tablet of
CF/CA at pre-dose and 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 6.0,
8.0, 10.0 and 12.0 h, in heparinized glass vials. The blood
samples were immediately centrifuged at 4000 rpm for 10 min
at room temperature. The separated plasma samples were
stored at 2072 1C till the analysis. Plasma samples were
spiked with the IS and processed as per the extraction
procedure described earlier. Clinical samples were assayed by
the validated LC–MS method.
2.8. Pharmacokinetic analysis
The plasma concentration–time proﬁle obtained was fed into
pharmacokinetic solutions, Add-on program to Microsoft
excel, to determine the pharmacokinetic parameters. The
maximum concentration (cmax) and the corresponding peak
time (tmax) was determined by the inspection of the individual
drug plasma concentration–time proﬁles. The elimination rate
constant (Kel) was obtained from the least-square ﬁtted
terminal log-linear portion of the plasma concentration–time
proﬁle. The elimination half-life (t1/2) was calculated as 0.693/
Kel. The area under the plasma concentration time curve from
0 to 12 h (AUC0–12 h) was calculated by the linear trapezoidal
rule. The area under the curve from 0 h extrapolated to
inﬁnity (AUC0–N) was calculated as AUC0–12 hþCt/Kel where
Ct is the last concentration.3. Results and discussion
3.1. LC–MS analysis
LC–APCI–MS parameters were tuned in both positive and
negative ionization modes for the analytes. Good response was
achieved in negative ionization mode. Fig. 1(A) and (B) showsspectrum of CF (A) and CA (B).
J.S.K. Nagarajan et al.288the deprotonated molecular ions of CF (m/z 362
([M–H])) and potassium salt of CA (m/z 198 ([M–K])),
respectively, without any evidence of adduct formation. Owing
to its high selectivity, quantitation of CF and CA were carried
out through SIM mode at m/z 362 and 198. The chromato-
graphic conditions, especially the composition of mobile phase,
were optimized through a number of trials to achieve good
resolution and symmetric peak shapes for the analytes and the
IS. Separation was attempted using various combinations of
methanol, acetonitrile and buffer on a Phenomenex C18
column. It was found that a mixture of methanol: acetonitrile:
2 mM ammonium acetate (pH 3.5) (25:25:50, v/v/v) could
achieve this purpose and was ﬁnally adopted as the mobileFig. 2 Typical SIM Chromatogram of blank plasma (A), and hum
100 mg/mL of IS (B).phase. The retention time of CF, CA and the IS were 3.5, 2.5
and 4.9 min, respectively.3.2. Speciﬁcity and selectivity
The degree of interference by endogenous plasma constituents
with the analytes and the IS was assessed by inspection of
chromatograms derived from processed blank plasma sample.
As shown in Fig. 2, no signiﬁcant direct interference in the
blank plasma traces was observed from endogenous sub-
stances in drug-free plasma at the retention time of the
analytes and IS.an plasma spiked with 50 mg/mL of CF, 50 mg/mL of CA and
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A simple SPE with Sam prep, C18 (3 mL, 100 mg) extraction
cartridge using mobile phase as an eluent was provided cleanest
samples. The recoveries of analytes and the IS were good and
reproducible. Mean (n¼6) percent recovery values of CF and
CA were 92.6–94.6% and 93.9–95.7%, respectively (Table 1).
Assessment of matrix effect constitutes an important and
integral part of validation for quantitative LC–MS for
supporting pharmacokinetics studies. In the study of matrix
effects, concentrations of CF and CA were 93.2, 95.8 (LQC),
94.2, 94.6 (MQC) and 92.7, 94.3% (HQC) of nominal
concentrations, indicating that no signiﬁcant signal suppres-
sion or enhancement occurred in the ionization of CF and CA.3.4. Linearity and sensitivity
Linear calibration curves were obtained over the concentra-
tion range of 5.0–30000.0 ng/mL and 2.0–12000.0 ng/mL for
CF and CA, respectively. A typical regression equation for the
calibration curve was found to be y¼2.9x0.1 for CF and
y¼0.2xþ0.1 for CA. The regression coefﬁcient (r2) for both
the anlaytes was found to be 40.99.
The lowest limit of reliable quantiﬁcation for the analytes
was set at the concentration of the LLOQ and it was found
to be 5.0 ng/mL for CF with 93.5% accuracy and 4.6%Table 2 Stability studies of cefadroxil and clavulanic acid in hum
Stability test Cefadroxil
QCs
(ng/mL)
Mean7SD
(ng/mL)
Accuracy
(%)
Freeze–thaw (3 cycles at
2072 1C)
15 13.670.5 90.7
15,000 13650.07586.9 91.0
25,000 23576.071155.2 94.3
Short-term (at 25 1C for 8 h) 15 13.570.6 90.0
15,000 13363.07601.3 89.1
25,000 22882.07892.4 91.5
Long-term (at 2072 1C
for 3 months)
15 12.870.6 85.3
15,000 12376.07470.3 82.5
25,000 20554.07760.5 82.2
Stock solution (at 25 1C
for 8 h)
15 14.470.5 96.0
15,000 13962.07349.1 93.1
25,000 23844.07691.5 95.4
Table 1 Recovery, accuracy and precision studies of cefadroxil a
Analyte QCs
(ng/mL)
Concentration found
(Mean7SD; ng/mL)
Mean
recovery (%)
I
P
Cefadroxil 15 14.170.3 93.8 4
15,000 14187.07459.7 94.6 3
25,000 23155.17664.5 92.6 2
Clavulanic acid 10 9.570.3 94.8 3
5000 4787.07159.9 95.7 2
9000 8456.47209.7 93.9 1precision, while CA showed an LLOQ of 2.0 ng/mL with
92.7% accuracy and 4.2% precision. The present method was
proved to be sensitive than the former method [23].
3.5. Accuracy and precision
Accuracy and precision data for intra- and inter-day plasma
samples for CF and CA are presented in Table 1. The assay
values on both the occasions (intra- and inter-day) were found
to be within the accepted variable limits.
3.6. Stability
Stability of CF and CA was tested by analysis of QCs (n¼3)
under the following conditions: freeze–thaw stability (3 cycles) at
2072 1C, short-term stability at 25 1C, long-term stability at
2072 1C for 3 months and stock solution stability at 25 1C, the
mean% nominal values of the analytes were found to be within
715% of the predicted concentrations for the analytes at their
three QCs levels (Table 2). The results were found to be within
the acceptable limits during the entire validation.
3.7. Application
The validated LC–MS method was successfully applied to
measure the concentration of CF and CA in plasma samplesan plasma (n¼6).
Clavulanic acid
Precision
(%)
QCs
(ng/mL)
Mean7SD
(ng/mL)
Accuracy
(%)
Precision
(%)
3.8 10 9.370.3 93.0 3.3
4.3 5000 4577.0 7183.1 91.5 4.0
4.9 9000 8294.0 7132.7 92.2 1.6
4.2 10 8.970.3 89.0 3.3
4.5 5000 4283.07141.3 85.7 3.3
3.9 9000 7868.0739.3 87.4 0.5
4.8 10 7.970.3 79.0 3.3
3.8 5000 3795.0798.7 75.9 2.6
3.7 9000 7182.0764.6 79.8 0.9
3.2 10 9.470.3 94.0 3.3
2.5 5000 4834.0777.3 96.7 1.6
2.9 9000 8726.07165.8 96.9 1.9
nd clavulanic acid in human plasma (n¼6).
ntra-day Inter-day
recision (%) Accuracy (%) Precision (%) Accuracy (%)
.5 93.5 3.9 82.7
.6 94.8 4.4 84.6
.8 93.5 4.8 84.3
.9 94.4 4.0 82.7
.3 95.1 3.8 82.9
.7 95.5 3.2 84.7
Fig. 3 Pharmacokinetic proﬁles of CF (A), and CA (B) in human plasma following the oral administration of CF/CA (500/125 mg)
tablet to healthy volunteers (n¼12).
Table 3 Pharmacokinetic parameters of cefadroxil and
clavulanic acid (n¼12, Mean7SD).
Parameters Cefadroxil Clavulanic acid
cmax (ng/mL) 15460.070.1 5270.070.8
tmax (h) 1.570.0 2.070.0
Kel (1/h) 0.470.3 0.270.2
t1/2 (h) 1.870.2 3.070.5
AUC0–12 h (ng h/mL) 31040.170.6 18720.071.3
AUC0–N (ng h/mL) 32740.470.3 20540.070.9
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concentration (n¼12) vs time proﬁle of CF and CA is shown
in Fig. 3(A) and (B), respectively and the pharmacokinetic
data are listed in Table 3. Bioequivalence study protocols
generally recommend plasma sample collection for a time
period corresponding to three to four times the drug plasma
elimination half-life [26], which brings terminal concentrations
values of about 6% of the peak concentration value. Mean
peak plasma concentration of CF and CA is about 15500.0
and 5300.0 ng/mL respectively and their plasma concentra-
tions after four half-lives were 970.0 and 330.0 ng/mL,
respectively. Since the method LLOQ was 5.0 ng/mL and
2.0 ng/mL for CF and CA, respectively, its sensitivity is
adequate for the bioavailability studies. AUC0–12 h and
AUC0–N were calculated. The ratio of AUC0–12 h/AUC0N
was found to be 485% for all subjects, as recommended by
FDA guidelines [24–26].4. Conclusion
A simple, speciﬁc, sensitive, precise and accurate LC–MS
method was developed for the simultaneous quantiﬁcation of
CF and CA in human plasma and was fully validated as per
the FDA guidelines. Processing of the plasma sample using
SPE technique was proved to be rugged and provided cleanest
samples with good recoveries. The present method showed
suitability for pharmacokinetic studies in humans and it was
successfully applied to bioequivalence study of two drug
products containing combination of CF/CA. The sensitivity
and simplicity of the method makes it suitable for bioavail-
ability and bioequivalence studies and routine therapeutic
drug monitoring.Acknowledgments
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